Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2023. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of 31 January 2023): 4,311,803,712 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 217,124,760 Ordinary Shares.
- Total Voting Rights: 4,094,678,952.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports a static snapshot of share capital as of 31 January 2023 without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification regarding share counts and does not contain forward-looking statements or risk analysis.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,094,678,952) to determine notification thresholds under FCA rules.
- Confirm the number of shares held in Treasury (217,124,760) when calculating outstanding shares.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for revenue and profit metrics.